Special Issue

Migraine: Experimental Models and Novel Therapeutic Target

Message from the Guest Editors

Migraine research has been grossly underfunded and the interest in migraines from the pharmaceutical industry has been limited. All of this has now changed with the advent of a number of new drugs antagonizing the naturally occurring signalling molecule calcitonin gene-related peptide (CGRP). This is the first mechanism-based drug development for migraines, and it illustrates how basic research in human and animal models of migraines can identify valuable novel drug targets. There are already many validated human and animal experimental models, and this Special Issue brings together our knowledge about them. Experimental research has already identified several migraine mechanisms that are promising drug targets. However, knowledge of them is, to a large extent, limited to the research groups responsible for the research. In this Special Issue, the models and derived drug targets are comprehensively described in one volume. Combined with the projected enormous size of the migraine drug market the information in this Special Issue will hopefully stimulate the pharma industry to pay much more attention to migraine in the future. The unserved need is immense.

Guest Editors

Dr. Sarah Louise Tangsgaard Christensen

Danish Headache Center, Department of Neurology, Copenhagen University Hospital-Rigshospitalet, 2600 Glostrup, Denmark

Prof. Dr. Jes Olesen

Danish Headache Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, 2600 Glostrup, Denmark

Deadline for manuscript submissions

closed (15 August 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/162249

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

